BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Volrustomig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Volrustomig\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07000149-1985@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Volrustomig: Phase 1 readout est. (NCT07000149)
DESCRIPTION:Volrustomig\, phase 1.\nStudy: A Study to Investigate the Effic
 acy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1
 L Treatment for Advanced ccRCC\nEstimated primary completion: 29 January 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/volrustomig#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07000149
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04379596-1985@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:Volrustomig: Phase 2 readout est. (NCT04379596)
DESCRIPTION:Volrustomig\, phase 2.\nStudy: Ph1b/2 Study of the Safety and E
 fficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (
 DESTINY-Gastric03)\nEstimated primary completion: 4 May 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/volrustomig#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04379596
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04686305-1985@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Volrustomig: Phase 1 readout est. (NCT04686305)
DESCRIPTION:Volrustomig\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Pha
 se Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Witho
 ut Chemotherapy in Advanced or Metastatic HER2+\, Non-squamous NSCLC\nEsti
 mated primary completion: 30 June 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/volrustomig#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04686305
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06792695-1985@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Volrustomig: Phase 2 readout est. (NCT06792695)
DESCRIPTION:Volrustomig\, phase 2.\nStudy: A Study of Novel Study Intervent
 ions and Combinations in Participants With Colorectal Cancer\nEstimated pr
 imary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/volrustomig#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06792695
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06448754-1985@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Volrustomig: Phase 2 readout est. (NCT06448754)
DESCRIPTION:Volrustomig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Vol
 rustomig Priming Regimens Exploratory Phase II Platform Study\nEstimated p
 rimary completion: 30 July 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/volrustomig#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06448754
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05489211-1985@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Volrustomig: Phase 2 readout est. (NCT05489211)
DESCRIPTION:Volrustomig\, phase 2.\nStudy: Study of Dato-DXd as Monotherapy
  and in Combination With Anti-cancer Agents in Patients With Advanced Soli
 d Tumours (TROPION-PanTumor03)\nEstimated primary completion: 1 October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/volrustomig#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05489211
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06079671-1985@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20271126
DTEND;VALUE=DATE:20271127
SUMMARY:Volrustomig: Phase 3 readout est. (NCT06079671)
DESCRIPTION:Volrustomig\, phase 3\, Cervical Cancer.\nStudy: Study of Volru
 stomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Ce
 rvical)\nEstimated primary completion: 26 November 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/volrustomig#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06079671
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05702229-1985@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Volrustomig: Phase 2 readout est. (NCT05702229)
DESCRIPTION:Volrustomig\, phase 2.\nStudy: Novel Combinations in Participan
 ts With Locally Advanced Unresectable or Metastatic Gastric or Gastroesoph
 ageal Junction Adenocarcinoma\nEstimated primary completion: 30 November 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/volrustomig#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05702229
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03741426-1985@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Volrustomig: Phase 2 readout est. (NCT03741426)
DESCRIPTION:Volrustomig\, phase 2.\nStudy: WIRE - Novel Treatments in Renal
  Cell Cancer\nEstimated primary completion: 30 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/volrustomig#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT03741426
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943833-1985@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20280313
DTEND;VALUE=DATE:20280314
SUMMARY:Volrustomig: Phase 2 readout est. (NCT06943833)
DESCRIPTION:Volrustomig\, phase 2\, Cervical Cancer.\nStudy: A Study of Vol
 rustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)
 \nEstimated primary completion: 13 March 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/volrustomig#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06943833
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06097728-1985@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20281116
DTEND;VALUE=DATE:20281117
SUMMARY:Volrustomig: Phase 3 readout est. (NCT06097728)
DESCRIPTION:Volrustomig\, phase 3.\nStudy: MEDI5752 in Combination With Car
 boplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma\nEstimated p
 rimary completion: 16 November 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/volrustomig#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06097728
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06535607-1985@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Volrustomig: Phase 2 readout est. (NCT06535607)
DESCRIPTION:Volrustomig\, phase 2\, Cervical Cancer.\nStudy: Study of Volru
 stomig as Monotherapy or in Combination With Anti- Cancer Agents in Partic
 ipants With Advanced/Metastatic Solid Tumors\nEstimated primary completion
 : 30 November 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/v
 olrustomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06535607
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07065630-1985@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20290813
DTEND;VALUE=DATE:20290814
SUMMARY:Volrustomig: Phase 2 readout est. (NCT07065630)
DESCRIPTION:Volrustomig\, phase 2\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: Response-Adaptive Treatment in Untreated Locoregional HPV-Negative
  Head and Neck Cancer\nEstimated primary completion: 13 August 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/volrustomig#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07065630
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06129864-1985@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20300417
DTEND;VALUE=DATE:20300418
SUMMARY:Volrustomig: Phase 3 readout est. (NCT06129864)
DESCRIPTION:Volrustomig\, phase 3\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: A Global Study of Volrustomig (MEDI5752) for Participants With Unr
 esected Locally Advanced Head and Neck Squamous Cell Carcinoma Following D
 efinitive Concurrent Chemoradiotherapy\nEstimated primary completion: 17 A
 pril 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/volrustomi
 g#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 129864
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05061550-1985@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20300528
DTEND;VALUE=DATE:20300529
SUMMARY:Volrustomig: Phase 2 readout est. (NCT05061550)
DESCRIPTION:Volrustomig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neo
 adjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer\n
 Estimated primary completion: 28 May 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/volrustomig#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05061550
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04541108-1985@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Volrustomig: Phase 1 readout est. (NCT04541108)
DESCRIPTION:Volrustomig\, phase 1.\nStudy: Phase 0 Master Protocol for CIVO
  Intratumoral Microdosing of Anti-Cancer Therapies\nEstimated primary comp
 letion: December 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/volrustomig#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04541108
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
